Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroBo Pharmaceuticals has signed a conditional exclusive license agreement with Dong-A ST for the development and commercialisation of the latter’s cardio-metabolic therapies, DA-1241 and DA-1726.
Set of micrographs showing lobular necro-inflammation and interface hepatitis. Credit: Nephron/ commons.wikimedia.org.
Subscribe to our email newsletter
Under the deal terms, NeuroBo will undertake the development, regulatory and commercial works for the two therapies across the world excluding certain Asian-Pacific areas.
Dong-A will be responsible for manufacturing the clinical supplies and primary commercial supplies of the product at its manufacturing facility located in South Korea.
The new G-Protein-Coupled Receptor 119 (GPR119) agonist, DA-1241 promotes the key gut peptides GLP-1, GIP and PYY release, which play a key role in lipid metabolism, weight loss, and glucose metabolism.
It is suitable for oral administration and was seen to be well tolerated in phase I studies.
DA-1726 is a new oxyntomodulin (OXM) analogue that works as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist.
Its dual mechanism showed beneficial effects on weight loss compared with selective GLP-1 activity in animal models.
In the same models, DA-1726 has also demonstrated the ability to improve hepatic steatosis, inflammation and fibrosis compared with the GLP-1 agonist, semaglutide.
Currently, the two therapies are being assessed to treat obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes.
NeuroBo CEO and president Gil Price said: “The acquisition of these two cardiometabolic assets marks a seismic shift for NeuroBo, providing us with a highly promising, diversified pipeline with several upcoming value inflection points in the NASH and obesity space — areas with enormous market opportunity.
“Once the transaction has closed, which is contingent upon certain closing conditions, we will be uniquely positioned to initiate a phase 2a study of DA-1241 in NASH in the first half of 2023, with data expected in the second half of 2024.
“We also intend to initiate a phase 1a safety study of DA-1726 in the first half of 2023, for which data is expected in the second half of 2023.”
As per the license agreement, Dong-A will receive $22m upfront payment in Series A convertible preferred stock.
The company will also be eligible to receive milestone payments after achieving specific regulatory and commercial developments and will be entitled to royalties on net sales of the two products.
Subject to receipt of third-party financing to develop the assets and other customary closing conditions, the transaction is anticipated to be concluded in the third quarter of this year.
